Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

NCT07527143 | Not Yet Recruiting

• 1 other identifier: 25-011120
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.

Conditions

Endometrial Carcinoma

Outcome Measures

Primary Outcomes (1)

• Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test

  Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.

  Baseline (30-minute virtual interview)

Study Arms (1)

Observational

Participants complete a semi-structured interview on study.

Other: Non-Interventional Study

Interventions

Non-Interventional Study OTHER

Non-interventional study

Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

Observational

Eligibility Criteria

• Age: 45 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Self-identified Black females 45 years or older with an intact uterus recruited through Mayo Clinic in Rochester

You may qualify if:

• Self-identified Black individuals ≥ 45 years with an intact uterus
• Assigned female sex at birth
• Willing to participate in a 30-minute virtual interview

You may not qualify if:

• Previous or current diagnosis of endometrial cancer

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Related Links

• Mayo Clinic Clinical Trials

MeSH Terms

Conditions

Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Officials

• Shariska Harrington, MD

  Mayo Clinic in Rochester

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Clinical Trials Referral Office

CONTACT

855-776-0015; mayocliniccancerstudies@mayo.edu

Kelly Gunderson

CONTACT

507-422-1892

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 7, 2026
• First Posted: April 14, 2026
• Study Start: April 6, 2026
• Primary Completion (Estimated): April 6, 2027
• Study Completion (Estimated): April 6, 2027
• Last Updated: April 14, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)